News · 26 weeks59-42%
2025-12-282026-06-21
Mix3190d
- Insider16(52%)
- Other7(23%)
- SEC Filings5(16%)
- Market2(6%)
- Earnings1(3%)
Latest news
25 items- NEWSPrecigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study EncouragingMeg Flippin, Benzinga Staff WriterData reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare respiratory disease GERMANTOWN, MD / ACCESS Newswire / June 15, 2026 / Precigen Inc. (NASDAQ:PGEN) has gained an important advantage in the marketing of its new treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract. The commercial-stage precision medicines company was just granted orphan drug exclusivity by the FDA for PAPZIMEOS™ (zopapogene imadenovec-drba), its treatment for RRP, a disease that typically requires patie
- PRPrecigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community VoicesThird annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRPGERMANTOWN, Md. and FORT WORTH, Texas, June 11, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the Recurrent Respiratory Papillomatosis Foundation (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day. Observed each year
- INSIDERChief Financial Officer Thomasian Harry Jr. sold $182,614 worth of shares (41,884 units at $4.36), decreasing direct ownership by 7% to 554,535 units (SEC Form 4) (withholding obligation)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Commercial Officer Tennant Phil sold $131,986 worth of shares (30,272 units at $4.36), decreasing direct ownership by 18% to 139,369 units (SEC Form 4) to satisfy withholding tax4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Operating Officer Shah Rutul R sold $186,185 worth of shares (42,703 units at $4.36), decreasing direct ownership by 8% to 497,751 units (SEC Form 4) to cover withholding tax4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Legal Officer Lehr Donald P. sold $127,011 worth of shares (29,131 units at $4.36), decreasing direct ownership by 4% to 755,461 units (SEC Form 4) to cover withholding tax4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERPresident and CEO Sabzevari Helen sold $519,930 worth of shares (119,250 units at $4.36), decreasing direct ownership by 3% to 3,768,872 units (SEC Form 4) (tax withholding)4 - PRECIGEN, INC. (0001356090) (Issuer)
- PRPrecigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP5 complete responders have ongoing responses beyond 4 yearsFollow-up is ongoing; median duration of complete response has not yet been reachedNo new adverse safety events have been observed during long-term follow-upUS FDA granted seven-year period of orphan drug market exclusivity to PAPZIMEOSGERMANTOWN, Md., May 30, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced updated long-term follo
- INSIDERChief Financial Officer Thomasian Harry Jr. converted options into 87,500 shares, increasing direct ownership by 17% to 596,419 units (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Commercial Officer Tennant Phil converted options into 62,500 shares, increasing direct ownership by 58% to 169,641 units (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Operating Officer Shah Rutul R converted options into 90,000 shares, increasing direct ownership by 20% to 540,454 units (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERPresident and CEO Sabzevari Helen converted options into 250,000 shares, increasing direct ownership by 7% to 3,888,122 units (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Legal Officer Lehr Donald P. converted options into 62,500 shares, increasing direct ownership by 9% to 784,592 units (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- PRPrecigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United StatesFDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosisSeven-year period of PAPZIMEOS market exclusivity is effective through August 14, 2032PAPZIMEOS, the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis, is commercially available in the US GERMANTOWN, Md., May 27, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug exclusivity for PAPZIMEOS™ (zopapogene imadenov
- PRPrecigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare ConferenceGERMANTOWN, Md., May 26, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the company will participate in two upcoming investor events. The J.P. Morgan virtual fireside chat will be held on Monday, June 1, at 10:00 a.m. ET. The event will be hosted by Brian Cheng, Senior Biotech Analyst, J.P. Morgan. Precigen participants will include Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer.T
- SECPrecigen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PRECIGEN, INC. (0001356090) (Filer)
- SECSEC Form 10-Q filed by Precigen Inc.10-Q - PRECIGEN, INC. (0001356090) (Filer)
- PRPrecigen Reports First Quarter 2026 Financial Results and Business UpdatesPAPZIMEOS™ launch gaining strong momentum with $21.6 million in net product revenue in the first quarter of 2026 reflecting broad-based uptake across the USPatient hub enrollment continues to gain traction, with approximately 400 patients currently enrolled; a notable 25% of which are from the community setting, underscoring the breadth of PAPZIMEOS's reach and ease of administrationUpdated durability of response data for PAPZIMEOS will be presented at the upcoming ASCO Annual MeetingRRP Awareness Day will be hosted alongside the Recurrent Respiratory Papillomatosis Foundation on June 11 for the third consecutive year, reflecting the Company's ongoing commitment to the recurrent respiratory
- PRPrecigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13GERMANTOWN, Md., May 7, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release first quarter 2026 financial results and provide business updates on Wednesday, May 13, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in
- SECSEC Form DEFA14A filed by Precigen Inc.DEFA14A - PRECIGEN, INC. (0001356090) (Filer)
- SECSEC Form DEF 14A filed by Precigen Inc.DEF 14A - PRECIGEN, INC. (0001356090) (Filer)
- INSIDERSEC Form 4 filed by Lehr Donald P.4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERSEC Form 4 filed by Sabzevari Helen4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERSEC Form 4 filed by Shah Rutul R4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERSEC Form 4 filed by Tennant Phil4 - PRECIGEN, INC. (0001356090) (Issuer)
PGEN FAQ
6 questionsWhat does Precigen Inc. do?
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs...Where does PGEN stock trade?
Precigen Inc. (PGEN) is listed on NASDAQ.What sector and industry is PGEN in?
Precigen Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PGEN?
Precigen Inc. has had 4 recent analyst actions on file. The most recent action was from Analyst: Neutral on 2025-08-15. Recent price targets cluster around $700.00.What companies are similar to PGEN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PGEN side-by-side with any of them on Quantisnow.How can I track PGEN on Quantisnow?
Quantisnow aggregates Precigen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PGEN to receive live email and push alerts on every new disclosure.